01—Abstract
Summary
Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health reported third quarter 2024 revenue of $191.5 milliona, up 34% year over year from $143.0 million, driven by clinical test volume growth of 21% (excluding Shield), biopharma test volume growth of 40%, and higher Guardant360 reimbursement, including Medicare pricing of $5,000 effective January 1, 2024.
Precision oncology revenue rose 35% to $180.6 millionb. GAAP gross margin was 61% and non-GAAP gross margin excluding screening costs was 65%. GAAP net loss widened to $107.8 million from $86.1 million, largely because of an $18.3 million increase in unrealized and realized losses on the company's Lunit investment.
Non-GAAP net loss improved to $55.0 millionc from $79.2 million, and adjusted EBITDA loss narrowed to $56.2 million from $79.7 million. Management raised full-year 2024 revenue guidance to $720 to $725 million, representing 28% to 29% growth, from the prior range of $690 to $700 million. This is the third guidance increase of the year.
Free cash flow guidance was revised to a $(265) to $(275) million outflow, an improvement of $70 to $80 milliond versus 2023. Non-GAAP operating expense guidance of $720 to $730 million and the 61% to 63% non-GAAP gross margin excluding screening outlook were unchanged. The quarter also marked the commercial launch of Shield IVD following FDA approval, with a Medicare price of $920 effective August 1, 2024.
Cash, cash equivalents, restricted cash and marketable debt securities totaled $1.0 billion at quarter end. Investors should weigh the strong top-line momentum and improving cash burn against continued GAAP losses, high sales and marketing spend, and the volatility introduced by equity investment marks.
02—Key points
Key Highlights
- Q3 2024 revenue of $191.5 million, up 34% year over year, with precision oncology revenue up 35% to $180.6 million
- Clinical test volume (excluding Shield) grew 21% to 53,100 tests and biopharma test volume grew 40% to 10,500 tests; Guardant360 ASP exceeded $3,000
- Full-year 2024 revenue guidance raised for the third time this year to $720 to $725 million (28% to 29% growth), from $690 to $700 million
- Free cash flow improved to $(55.3) million in Q3 from $(80.2) million a year earlier; full-year FCF guidance improved to $(265) to $(275) million
- GAAP net loss widened to $107.8 million ($0.88 per share) from $86.1 million, driven by an $18.3 million increase in losses on the Lunit investment; non-GAAP net loss narrowed to $55.0 million
- Shield received Medicare pricing of $920 effective August 1, 2024, following its FDA-approved commercial launch; TissueNext Medicare pricing rises to $3,500 on January 1, 2025
- Cash, cash equivalents, restricted cash and marketable debt securities totaled $1.0 billion as of September 30, 2024
03—Questions
Frequently Asked Questions
Why did Guardant raise its 2024 revenue guidance?
Management attributed the raise to strong clinical and biopharma test volume growth and reimbursement tailwinds for Guardant360, including the Medicare rate increase to $5,000 effective January 1, 2024 and higher Medicare Advantage and commercial payer reimbursement. The company also cited adoption of the Guardant360 Smart Liquid Biopsy upgrade, which management said expanded both the breadth and depth of accounts.
Why did the GAAP net loss increase even though operating performance improved?
GAAP net loss rose to $107.8 million from $86.1 million mainly because of an $18.3 million year-over-year increase in net unrealized and realized losses on the company's investment in Lunit, Inc. Loss from operations actually improved to $(117.3) million from $(113.5) million on a GAAP basis, and non-GAAP loss from operations improved to $(66.3) million from $(90.0) million. Non-GAAP results exclude stock-based compensation and the Lunit-related marks, so investors should consider both views.
What is the significance of the Shield Medicare price of $920?
The $920 Medicare price, effective August 1, 2024, establishes reimbursement for Shield, the company's blood-based colorectal cancer screening test, shortly after its FDA approval and commercial launch. Management said the price recognizes Shield as an important new class of CRC screening. The filing also notes that CMS removed cost-sharing for a follow-on colonoscopy after a blood-based screening test, which could support adoption. Screening costs weighed on gross margin, which is why the company also reports gross margin excluding screening costs.
How strong is Guardant's balance sheet and cash position?
Cash, cash equivalents, restricted cash and marketable debt securities totaled about $1.0 billion at September 30, 2024, with $688.4 million in cash and equivalents and $310.7 million in short-term marketable debt securities. The company carries $1.14 billion of convertible senior notes, and total stockholders' equity was a deficit of $(60.1) million, compared with positive equity of $158.7 million at year-end 2023. The full-year free cash flow outflow guidance of $(265) to $(275) million implies continued cash consumption, though at a lower rate than 2023.
What should investors watch in the coming quarters?
Key items include whether clinical and biopharma volume growth continues at the Q3 pace, whether Guardant360 reimbursement tailwinds persist, the ramp of Shield volumes and its effect on screening gross margin, the TissueNext Medicare price increase to $3,500 on January 1, 2025, and progress toward the 61% to 63% non-GAAP gross margin excluding screening target. Investors should also monitor the Lunit investment's effect on GAAP results and the company's path toward free cash flow breakeven.
04—Continue